Skip to main content

Advertisement

Table 1 Clinical and economic inputs

From: Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Input Parameters Mean Lower bound Upper bound Source
Mortality rate with appropriate empiric treatment 0.013 0.012 0.014 Edelsberg et al. [13]
Mortality rate with inappropriate empiric antibiotic 0.095 0.086 0.105 Edelsberg et al. [13]
Duration of empiric therapy 3 days 3 days 3 days Assumption
Total LOS for IAAT (inc. empiric therapy) 6.9 days 6.8 days 7 days Edelsberg et al. [13]
Total LOS for IIAT (inc. empiric therapy) 11.5 days 11.3 days 11.9 days Edelsberg et al. [13]
Health utility for survivors 0.85 0.70 1.00 Assumption based on Jansen et al. [25]
Discount rate 3.0% 3.0% 3.0% AMCP [26]
Hospital cost per day (average) $2558.55 $2046.84 $3070.26 HCUP [27]
Drug acquisition costs per day   
 Ceftolozane/tazobactam plus metronidazole $253.20 Analy$ource [29]
 Aztreonam $84.24 Analy$ource [29]
 Cefepime $23.04 Analy$ource [29]
 Ceftazidime $36.66 Analy$ource [29]
 Ceftriaxone $6.40 Analy$ource [29]
 Ciprofloxacin $5.26 Analy$ource [29]
 Doripenem $125.22 Analy$ource [29]
 Imipenem $73.12 Analy$ource [29]
 Levofloxacin $6.24 Analy$ource [29]
 Meropenem $81.51 Analy$ource [29]
 Piperacillin/tazobactam $43.08 Analy$ource [29]
 Tigecycline $238.34 Analy$ource [29]
 Salvagea $164.31 Analy$ource [29]
Health care expenditure incurred per year   
 <25 years $477 Basu [18]
 25 to 34 years $790 Basu [18]
 35 to 44 years $947 Basu [18]
 45 to 54 years $1422 Basu [18]
 55 to 64 years $2106 Basu [18]
 65 to 74 years $2758 Basu [18]
 75 years and above $3100 Basu [18]
  1. aSalvage therapy consists of meropenem + colistin for cost purposes
  2. LOS Length of stay, IAAT Initial appropriate antibiotic therapy, IIAT Initial inappropriate antibiotic therapy